Bayer and Attralus announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m), two investigational molecular imaging agents for the diagnosis of cardiac amyloidosis, from Attralus. This strategic acquisition reinforces Bayer’s ambition to expand in the rapidly growing field of molecular imaging and supports the company’s broader precision cardiology strategy.

“With this strategic acquisition and the integration of novel molecular tracers into our development portfolio, we are advancing Bayer’s innovation strategy. AT-01 and AT-05 are precisely engineered to detect cardiac amyloidosis with high accuracy, enabling timely intervention and improved patient outcomes–a clear extension of our commitment to tackling cardiovascular disease and addressing significant unmet needs,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President—Pharmaceuticals Division, Bayer.

The acquired molecular imaging portfolio consists of AT-01 (124-Iodine-evuzamitide, a tracer for Positron Emission Tomography; PET) in phase III of clinical development and AT-05 (PAR-Peptide + technetium-99m, a tracer for Single Photon Emission Computed Tomography; SPECT) in phase I of clinical development, focused on the diagnosis of cardiac amyloidosis. The development of these tracers has the potential to address the urgent need for earlier and accurate diagnosis of systemic and specifically cardiac amyloidosis, a rarely diagnosed and often fatal heart disease that affects an estimated 400,000 people globally. With current methods, these conditions are often underdiagnosed and difficult to detect.

“With new therapies emerging for often insufficiently treated conditions such as cardiac amyloidosis, it becomes increasingly relevant to precisely detect and monitor diseases on the molecular level. This acquisition marks our entry into diagnostic tracers. Leveraging our expertise in medical imaging–including our pipeline and portfolio in advanced fluid delivery devices for nuclear medicine–it supports our ambition to expand in the growing field of molecular imaging. Building on Attralus’ research and development expertise, we will further advance scientific progress with the aim to broaden diagnostic options and make a meaningful difference for people living with cardiac amyloidosis,” said Nelson Ambrogio, President—Radiology, Bayer.

The global market for radio-diagnostic tracers was valued at approximately USD 3 billion in 2024 and is projected to grow significantly in the coming years. With its comprehensive portfolio in radiology, its expertise in medical imaging and clinical development and global commercial infrastructure, Bayer is positioned to accelerate innovation and deliver integrated offerings that address evolving clinical needs and have the potential to improve patient outcomes worldwide.

“We are excited to finalise this agreement with Bayer, whose expertise and global footprint in radiology will help to accelerate the development and launch of AT-01 and AT-05, our two novel diagnostic imaging agents for systemic amyloidosis. Despite recent progress in systemic amyloidosis, most patients continue to remain undiagnosed or are diagnosed too late in their disease progression. Consistent with Attralus’ mission, we believe that these pan-amyloid imaging agents will enable earlier diagnosis and treatment, leading to improved patient outcomes. Bayer’s commitment to scientific rigour and patient impact makes them well-suited to bring these agents to clinicians and patients worldwide. Attralus will now focus on advancing its innovative pan-amyloid removal therapeutics, with AT-02 in phase II and next-generation candidates in pre-clinical development,” said Glen Firestone, President, Attralus.